Translational Development Acquisition (TDACU) Shares Outstanding (Weighted Average) (2023 - 2026)

Translational Development Acquisition has reported Shares Outstanding (Weighted Average) for 4 years, with the latest figure at $17.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 270.37% year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.2 million (up 270.37% YoY), and the FY2025 full-year result was $4.7 million, down 70.33% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $17.2 million, up from $15.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $17.2 million in Q3 2025, with the low at $4.0 million in Q4 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $9.7 million across 4 years, with a median of $4.7 million in 2025.
• The largest YoY upside for Shares Outstanding (Weighted Average) was 325.93% in 2025 against a maximum downside of 0.0% in 2025.
• Translational Development Acquisition's Shares Outstanding (Weighted Average) stood at $4.0 million in 2023, then jumped by 287.65% to $15.7 million in 2024, then changed by 0.0% to $15.7 million in 2025, then rose by 9.87% to $17.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $17.2 million (Q1 2026), $15.7 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.